👉Growth of injectables has been the fastest across all delivery forms.
👉It accounts for 42% of the total market share of drug delivery forms in the pharmaceutical market.
(2/7)
👉Increased cases of chronic diseases like cancer, diabetes & cardiovascular disorders is driving growth in injectables drug delivery market. Covid-19 pandemic also created an increased demand for vaccination.
(3/7)
Now, lets talk about Gland pharma Q1 FY23 update📊📊
👉 The Company faced multiple headwinds like supply chain disruptions, cost escalation and shutdown of their insulin line during Q1 FY23 which impacted their revenue, EBITDA and net profit which declined 26%, 38% & 34.6% on a yoy basis, respectively.
(4/7)
Now, time for Gland Pharma's future outlook🎯🎯
👉 They have a capex guidance of Rs. 300 crores in FY23.
👉 The company's biologics segment could start revenue from Q4 FY23.
👉 The company also wants to commence business in China which has an addressable market size of $1 billion.
(5/7)
👉 Company's revenue is expected to improve with the easing of supply side issues.
👉 Company is vertically integrated & has 4 API facilities
(6/7)
Now, lets have a look at the charts of Gland Pharma📉📈
Weekly chart of Gland Pharma - Still looks weak from the chart perspective. Lets see if it breaks the support or respects it.
(7/7)
I hope my thread helped you in knowing Gland pharma better than before. Please don't forget to join our telegram channel its absolutely FREE & we are doing a lot of hard work here. telegram.me/TheMarketLearn…
Thanks for reading,
The Market Learner.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
👉Business model
👉Management
👉Objectives of the issue
👉Business Overview
👉Product portfolio
👉Competitive Strengths
👉Business Strategies
👉My personal view